Abstract: A formulation for topical application, the formulation comprising a waterborne polyurethane polymer; a thickening agent; a humectant, at least one sunscreen active agent, and an emulsifying agent.

Abstract: The invention relates to cosmetic and/or dermatological compositions more particularly intended for artificially tanning and/or browning the skin, comprising, in a cosmetically acceptable support, at least one self-tanning agent and at least one N-acyl amino acid ester.

Abstract: A composition for forming a cosmetic mask including: at least one colorant; and silica, wherein when the composition is combined with water, the amount of the colorant and the silica is effective to provide a color change upon drying is disclosed. The composition may be useful as a skin care formulation, such as for a facial mask, a cleanser, and the like.

Abstract: The invention relates to a process for the manufacture of a colored make-up cosmetic composition which makes it possible to produce a transparent or translucent colored coat on the skin, lips or superficial body growths, comprising the following successive stages:

Abstract: Provided is a deodorant having excellent masking and deodorizing effects of scalp odor, body odor and foot odor.

Abstract: The invention refers to an anti-sweat cosmetic which is suitable for use on the whole body and whose ingredients are almost entirely plant-based. The anti-perspiration cosmetic contains 0.01 to 5% by weight of a mixture of the extract of the overground plant parts of Equisetum arvense and the essential oil of Salvia officinalis; 0.01 to 5% by weight of a mixture of the extracts of Hamamelis virginia and Quercus infectoria; 0.5 to 15% by weight of pulverized bamboo wood (Bamboo Powder) the particle size of which is 15 &mgr;m or smaller; ad 100% by weight cosmetic auxiliaries, carrier substances or further active agents or mixtures thereof.

Abstract: Provided is a resin powder for a dermatologic composition composed of resin particles having an average volume particle size of 2.0 to 20.0 &mgr;m, a shape factor SF1 of 110 to 140 and an average volume particle size distribution GSDv of 1.3 or less. Also disclosed are a skin cleansing composition and a cosmetic composition containing the resin powder, and a preparation process of the resin powder.

Abstract: Compositions of matter comprising benzoate esters of hydroxyl terminated polyether polysiloxane copolyols, in particular dimethicone copolyol benzoates, and process for preparing same. The benzoate esters are useful for personal care cleansing products, such as bar and liquid soaps, skin and hair care products and textiles and fibers. The compounds are prepared by reacting benzoic acid with hydroxyl terminated polyether polysiloxane copolyols.

Abstract: The present invention relates to stable aqueous emulsions of liquid alkoxytrimethylsilanes comprising a continuous aqueous phase, a discontinuous organic and/or alkoxytrimethylsilane phase and an emulsification system. The emulsification system comprises two emulsifying agents, an organosilicone hydrophobic emulsifying agent and an organosilicone hydrophilic emulsifying agent. Emulsions of this type are especially useful for delivery of liquid alkoxytrimethylsilanes to the surface and upper layers of the stratum corneum. A method for preparing these emulsions is also disclosed.

Abstract: Hair treatment compositions comprising a surfactant, a dispersed insoluble benefit agent, and PTFE microparticles. The use of PTFE microparticles as a deposition aid for a dispersed insoluble benefit agent in an aqueous hair treatment composition is also described.

Abstract: A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention.

Abstract: Cosmetic preparations, in particular shampoos, are described which comprise oxiconazole nitrate as antidandruff agent.

Abstract: N-halamine biocidal materials and coatings are provided. Monomeric oxazolidinones or hydantoins are homopolymerized or copolymerized with other monomers so as to produce materials or coatings, which upon exposure to solutions of chlorine or bromine become biocidal. The biocidal materials and coatings are effective at inactivating microorganisms upon surface contact and are regenerable following loss of efficacy upon further exposure to solutions of chlorine or bromine. Surfaces which could be treated with the materials and coatings include, but are not limited to: glass, plastic, metals, fibers, and wood for use in pool and tank liners, food wrappers, catheters, paints, tiles, shower walls, fabrics, sterile bandages, pipes, medical and dental coatings, preservatives, and the like.

Abstract: Method for preparing biocidal halogenated polystyrene hydantoins. The biocidal polymers poly-1,3-dichloro-5-methyl-5-(4′-vinylphenyl)hydantoin, poly-1,3-dibromo-5-methyl-5-(4′-vinylphenyl)hydantoin, and their monohalogenated alkali metal salts and protonated derivatives have been prepared as porous beads by use of highly crosslinked polystyrene beads as starting materials. The porous beads will be useful in water and air disinfection applications when employed in cartridge filters and carafes (for water), as well as for controlling noxious odor when mixed with absorbent materials in items such as disposable diapers, incontinence pads, bandages, sanitary napkins, pantiliners, mattress covers, shoe inserts, sponges, animal litter, carpets, fabrics, and air filters or the like.

Abstract: Method for preparing biocidal halogenated polystyrene hydantoins. The biocidal polymers poly-1,3-dichloro-5-methyl-5-(4′-vinylphenyl)hydantoin, poly-1,3-dibromo-5-methyl-5-(4′-vinylphenyl)hydantoin, and their monohalogenated alkali metal salts and protonated derivatives have been prepared as porous beads by use of highly crosslinked polystyrene beads as starting materials. The porous beads will be useful in water and air disinfection applications when employed in cartridge filters and carafes (for water), as well as for controlling noxious odor when mixed with absorbent materials in items such as disposable diapers, incontinence pads, bandages, sanitary napkins, pantiliners, mattress covers, shoe inserts, sponges, animal litter, carpets, fabrics, and air filters or the like.

Abstract: The present invention relates to an antibacterial aqueous solution comprising a complex of an anionic surfactant, a polycationic antibacterial agent and water.

Abstract: The present invention provides medicament-containing cyanoacrylate adhesive formulations for sealing wounds.

Abstract: Phenolic polymers are prepared by oxidizing and polymerizing starting organic compounds comprising at least one hydroxyl group and at least one carbonyl group or at least two hydroxyl groups on an aromatic structure. One or more inorganic compounds or salts is added and the solution is allowed to stand at about 20° C. to 80° C. for a period of about at least 2 hours. Salt molecules as well as starting compounds and other low molecular-weight materials below about 500 to about 10,000 daltons are removed from the product solution. Purified phenolic polymers are prepared in concentrated aqueous solution or in dried powder form in a final step, if necessary. The resultant phenolic polymers exhibit physicochemical properties strongly resembling those of typical commercially-available natural-product soil extracts. The materials are active influenza anti-viral agents, and are effective in anti-viral compositions for treating or preventing influenza viral diseases.

Abstract: The present invention is directed to biologic-chemical herbicide compositions (BCHs) for controlling or preventing weeds that include one or more chemical herbicides and microorganisms including gram-positive and/or gram-negative bacteria and yeast. The addition of a biologic microbial component to one or more chemical herbicides significantly increases the efficacy of the chemical herbicide thereby permitting lower amounts to be used to achieve a desired level of weed control. Any chemical herbicide or combination of herbicides can be used, including fatty acid herbicides like Round-UP®. The BCHs typically also include an optional nutrient component in an amount sufficient to support the growth and replication of the microorganisms. If the BCH is applied to soil rich in nutrients, or if the crops would support the growth of the microorganisms in the BCHs, then the nutrients can be omitted.

Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.

Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

Abstract: The invention relates to a vector for the gene therapeutic treatment of tumours, especially in connection with radiotherapy. Said vector is provided with a therapeutic gene in the DNA sequence thereof. The gene is controlled by the promoter for the catalytic subunit of the telomerase or by the promoter for cyclin A.

Abstract: The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and/or malignant and/or cancerous cell comprising contacting said cell with a VSV vector of the present invention.

Abstract: Activated lymphocytes are administered to a cancer patient at least five or more times within eight months after performing surgical and chemotherapeutic treatment or radiotherapy for treating cancer particularly liver cancer, so that recurrence of the cancer can be prevented over a long period of five or more years. The activated lymphocytes to be administered while performing treatment of cancer may be autologously derived from a cancer patient or collected from the other cancer patient at need. The activated lymphocytes can be cultivated for proliferating or activating lymphocyte cells collected in the presence of solid-phase anti-CD3 antigen and interleukin 2.

Abstract: In a first aspect, the present invention features methods for differentiating DNA species originating from different individuals in a biological sample. These methods may be used to differentiate or detect fetal DNA in a maternal sample or to differentiate DNA of an organ donor from DNA of an organ recipient. In preferred embodiments, the DNA species are differentiated by observing epigenetic differences in the DNA species such as differences in DNA methylation. In a second aspect, the present invention features methods of detecting genetic abnormalities in a fetus by detecting fetal DNA in a biological sample obtained from a mother. In a third aspect, the present invention features methods for differentiating DNA species originating from an organ donor from those of an organ recipient. In a fourth aspect, the present invention features kits for differentiating DNA species originating from different individuals in a biological sample.

Abstract: Cells are profiled with respect to their expression of cell surface molecules, and ability to respond to external stimulus in the microenvironment. External stimuli include cell-cell interactions, response to factors, and the like. The cells are arrayed on a planar or three-dimensional substrate through binding to immobilized or partially diffused probes. Probes of interest include specific binding partners for cell surface molecules, signaling cues that act to regulate cell responses, differentiation factors, etc., which may be arrayed as one or a combination of molecules.

Abstract: A method of treating congestive heart failure (CHF) in a human patient comprises treating an aliquot of the patients blood ex vivo with at least one stressor selected from the group consisting of a temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering the aliquot of treated blood to the patient. The treatment can be used on its own or as an adjunctive therapy in combination with conventional CHF treatments.

Abstract: The invention relates to developments in the treatment of diabetes in mammals.

Abstract: The present invention relates generally to the fields of cancer therapy and gene therapy. More particularly, it demonstrates that PEA3, as exemplified by mPEA3 and hPEA3, is a tumor suppressor and may be used to treat various forms of cancer, for example neu- or ras-mediated cancers.

Abstract: A method for induction of endogenous heat shock protein in tumor cells using a simple heat shock treatment which provides a simple and inexpensive method for augmenting antitumor vaccine potency. The method comprises administering to a mammal tumor cells which have been subject to a heat shock condition sufficient to cause induction of endogenous heat shock protein therein. Also disclosed is a composition for enhancing tumor cell immunogenicity comprising a therapeutically effective amount of attenuated tumor cells which have been subject to a heat shock condition.

Abstract: The invention provides a method for activating a T lymphocyte by contacting the T lymphocyte with a dendritic cell (DC) that presents a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DC may be pulsed with a TRT polypeptide or may comprise a recombinant polynucleotide encoding a TRT such as hTRT. The invention also provides DCs comprising a recombinant TRT polynucleotide. The methods and compositions of the invention are used in prevention and treatment of cancers and other cell proliferation diseases or conditions.

Abstract: The invention relates to microfabricated membranes and matrices that have a highly controlled and complex three-dimensional topography. The new microfabricated membranes and matrices can be prepared of man-made as well as natural materials, such as materials found in naturally occurring membranes, and thus can be made in the form of tissue substitutes or analogs, such as basal lamina, dermal, or skin analogs.

Abstract: Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or indirect and utilizes energy, enhancement compositions, and/or living organisms to enhance the cells and/or cell products produced by organs and suborgans.

Abstract: The present invention relates to the use of lactic acid bacteria capable of adhering to the mucosa of the intestine and especially colonizes it for the treatment of disorders associated with peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the treatment of peritonitis caused by cirrhosis of the liver. Specifically, the present invention relates to a method for preventing and/or treating disorders associated with peritonitis in a patient in need of such treatment. This method includes administering to the patient a lactic acid bacterium that is capable of adhering to the intestine's mucosa and essentially colonizes it for the preparation of an ingestable carrier. The invention also relates to a peritonitis treating composition of a lactic acid bacterium that is capable of adhering to the intestine's mucosa and essentially colonizes it for the preparation of an ingestable carrier. The carrier is preferably a food or pharmaceutical composition.

Abstract: The invention provides methods for producing antibodies by transplanting a cell that produces an antibody of interest into a mammal and isolating the desired antibodies from the mammal. The invention also features methods of transplanting antibody-producing cells into a mammal.

Abstract: The present invention relates to methods of treating parasitic diseases which are mediated by cysteine proteases by administration of 4-amino-azepan-3-one protease inhibitors. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.

Abstract: The invention relates to a method and composition for a selective apoptosis factor that will specifically kill cancer and other target cells but not normal cells. The method is for use in the cancer therapy, for anti-aging, bone disease as well as other applications in human or animals. This invention is focused on the alpha 2-HS glycoproteins (AHSG) and their related clones.

Abstract: The present invention provides a human glutathione s-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.

Abstract: The present invention provides biotechnologically useful oligo(ethylene glycol)-terminated 1,2-dithiolane compositions and conjugates of these compositions with biological or non-biological receptor, ligand, sequestering, or reporter moieties. The invention also provides methods for the preparation of these compositions. Further, the invention provides self-assembled monolayer (SAM) compositions on a metal and methods for their preparation.

Abstract: DNA isolates coding for human DNase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of human DNase useful in therapeutic or diagnostic compositions.

Abstract: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Abstract: A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF165 C-terminal domain fused to a wound-healing substance such as leptin.

Abstract: The present invention provides to methods of preventing, treating or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof comprising administering to a subject in need thereof one or more CD2 antagonists and at least one other prophylactic or therapeutic agent. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder.

Abstract: A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.

Abstract: A therapeutic delivery system efficiently introduces biologically active molecules to mammalian cells without the use of synthetic polymers or biopolymer coatings. Surface modification of a metal support, such as a medical device, results in a single molecular layer that can fasten various molecules, thereby minimizing any cellular inflammatory response while enhancing biocompatibility.

Abstract: This invention is in the field of immunology. More specifically, it relates to compositions and methods for identifying, treating and preventing cancer by targeting the extracellular domains of the frizzled receptor family of proteins.

Abstract: The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CDA cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immuno sorption in conjunction with the administration of an autoimmune inhibitor.

Abstract: This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

Abstract: Methods of diagnosing and treating mammalian tumors with molecules including anti-estrogen receptor immunoglobulin polypeptides are provided. In an illustrative embodiment, anti-estrogen receptor immunoglobulin polypeptides specific to distinct epitopes of the ligand-binding domain of estrogen receptor are contacted with membrane-associated estrogen receptor under conditions which allow binding of the anti-estrogen receptor immunoglobulin polypeptide to a degree sufficient to inhibit tumor growth by inhibiting the activation of the membrane-associated estrogen receptor. Injectable compositions for treating certain mammalian tumors with monoclonal antibodies and methods for diagnosing mammalian cancers which express an estrogen receptor associated with the surface membrane of the cells are also disclosed. Further, alternate methods for blocking intracellular signal transduction emanating from the activation of membrane-associated estrogen receptor forms are also presented.

Abstract: Methods for limiting apoptosis in a cell population by contacting such cells with a hydrophilic bile acid, such as ursodeoxycholic acid (UDCA), salts thereof, and analogs thereof (e.g., glyco- and tauro-ursodeoxycholic acid).